MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Down 17.8% in March

MiNK Therapeutics, Inc. (NASDAQ:INKT) was the recipient of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 24,000 shares, a decrease of 17.8% from the March 15th total of 29,200 shares. Based on an average daily volume of 29,500 shares, the short-interest ratio is presently 0.8 days. Approximately 2.4% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of MiNK Therapeutics in a research note on Tuesday, March 18th.

MiNK Therapeutics Stock Performance

Shares of MiNK Therapeutics stock traded down $0.20 during trading on Friday, reaching $7.63. The company had a trading volume of 2,273 shares, compared to its average volume of 14,681. The company has a market cap of $30.26 million, a price-to-earnings ratio of -1.96 and a beta of 0.15. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $13.79. The firm’s fifty day moving average is $8.59 and its 200-day moving average is $7.85.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.12). On average, research analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.